Spherix: Makers of Naturlose (tagatose), a natural, low-calorie sugar made from whey that may be useful as a treatment for Type 2 diabetes

home | sitemap

Spherix Receives NASDAQ Bid Price Deficiency Letter
>more»

Spherix Expands Phase 3 Naturlose Diabetes Trial Outside Of The U.S.
>more»

Spherix Reports 1st Quarter Earnings
>more»

Spherix Holds Annual Shareholders Meeting
>more»

Market Research Shows Spherix’s Naturlose® Readily Accepted by Diabetes Patients Meets MD’s Treatment Need
>more»

Spherix D-Tagatose To Be Supplied By Inalco S.P.A.
>more»

Spherix Hires Key Employees
>more»

Spherix Reports 2007 Financial Results
>more»

||View All||

Innovative biotechnology solutions for nutrition and health.
Our BioSpherix Division is dedicated to research and product development for innovations in the biotechnology industry. Spherix is currently running a Phase 3 clinical trial to study the use of Naturlose® as a treatment for Type 2 diabetes.

Learn more»

Expert support through the lifecycle of our clients' products.
Spherix Health Sciences Consulting provides expert support throughout the lifecycle of our clients’ products.

Learn more»

Spherix CEO, Dr. Claire Kruger, Quoted at Recent International Probiotics Association Conference
NutraUSA FoodUSA

Spherix Hires Renowned Toxicologist, Dr. Andrew Wallace Hayes, as Principal Consultant
>more»

Spheirx Supports Education in Developing Countries
>more»

Growth Achieved In Spherix’s Health Sciences Consulting Busines
Phase 3 Clinical Trial on Track, Market Research Contracts Signed
>more»

Spherix Launches Health Sciences Consulting Business Line.
Dr. Claire Kruger Tapped to Lead New Division; Will Become CEO after Sale of InfoSpherix
Naturlose to Remain Spherix’s Primary Focus
>more»